Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MODERNA TO PAY $950 MILLION WITH NO FUTURE ROYALTIES TO RESOLVE ALL GLOBAL LITIGATION; CORRESPONDING CHARGE EXPECTED IN Q1 2026 DISTRICT COURT'S SECTION 1498 DECISION TO BE APPEALED TO THE FEDERAL CIRCUIT COURT OF APPEALS WITH POTENTIAL ADDITIONAL PAYMENT CONTINGENT ON THE OUTCOME; NO ACCRUAL RECORDED FOR POTENTIAL ADDITIONAL PAYMENT AS LOSS IS NOT CONSIDERED PROBABLE 2026 YEAR-END CASH AND CASH EQUIVALENTS NOW EXPECTED TO BE IN THE RANGE OF $4.5 - $5.0 BILLION CAMBRIDGE, MA / ACCESS NEWSWIRE / MARCH 3, 2026 / MODERNA, INC. (NASDAQ:MRNA) TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SETTLEMENT AGREEMENT WITH ARBUTUS BIOPHARMA CORPORATION AND GENEVANT SCIENCES GMBH RESOLVING ALL LITIGATION WORLDWIDE, INCLUDING BETWEEN THE PARTIES IN THE U.S. DISTRICT COURT FOR THE DISTRICT OF DELAWARE. THE SETTLEMENT RESOLVES ALL WORLDWIDE ARBUTUS/GENEVANT LITIGATION RELATED TO SPIKEVAX AND MRESVIA AND PROVIDES CERTAINTY GOING FORWARD FOR MODERNA'S FULL INFECTIOUS DISEASE PORTFOLIO, INCLUDING MNEXSPIKE, MCOMBRIAX AND ITS FUTURE VACCINE PIPELINE, WITH NO FUTURE ROYALTIES OWED.

MODERNA RESOLVES GLOBAL PATENT LITIGATION WITH ARBUTUS/GENEVANT

MODERNA TO PAY GENEVANT AND ARBUTUS $950 MILLION UPFRONT AND AN ADDITIONAL $1.3 BILLION CONTINGENT UPON A FAVORABLE RESOLUTION OF MODERNA'S SECTION 1498 APPEAL IF THE $1.3 BILLION PAYMENT IS REALIZED, THIS SETTLEMENT WILL BE THE LARGEST DISCLOSED PATENT SETTLEMENT PAID IN THE PHARMACEUTICAL INDUSTRY AND THE SECOND LARGEST IN ANY INDUSTRY SETTLEMENT HOLDS MODERNA ACCOUNTABLE FOR INFRINGEMENT AND PROVIDES FOR THE COURT TO ENTER JUDGMENT OF NO INVALIDITY ON THE FOUR GENEVANT/ARBUTUS PATENTS ASSERTED IN THE CASE GENEVANT GRANTS MODERNA A GLOBAL NON-EXCLUSIVE LICENSE TO ITS LNP DELIVERY TECHNOLOGY FOR SM-102-CONTAINING MRNA VACCINES FOR INFECTIOUS DISEASE AND A COVENANT NOT TO SUE FOR CERTAIN GENEVANT/ARBUTUS PATENTS AND MODERNA PRODUCTS, ENDING ALL PATENT-INFRINGEMENT LITIGATION AGAINST MODERNA ARISING FROM ITS UNAUTHORIZED USE OF THE TECHNOLOGY IN ITS COVID-19 VACCINES PFIZER/BIONTECH LITIGATION IS ONGOING IN THE UNITED STATES FOLLOWING A FAVORABLE MARKMAN RULING ISSUED IN SEPTEMBER 2025; COMIRNATY SALES REPRESENT ~2/3 OF GLOBAL COVID-MRNA VACCINE SALES TO DATE ARBUTUS ANNOUNCES THAT IT IS CURRENTLY EVALUATING A RETURN OF CAPITAL TO SHAREHOLDERS FOR THE THIRD QUARTER OF CALENDAR YEAR 2026, IN CONJUNCTION WITH THE UPFRONT PAYMENT ROIVANT WILL HOST AN INVESTOR CALL TO DISCUSS THESE UPDATES TODAY, MARCH 3, 2026, AT 4:45 P.M. ET BASEL, SWITZERLAND AND VANCOUVER, BRITISH COLUMBIA, MARCH 03, 2026 (GLOBE NEWSWIRE) -- GENEVANT SCIENCES, A LEADING NUCLEIC ACID DELIVERY COMPANY WITH WORLD-CLASS PLATFORMS AND A ROBUST LIPID NANOPARTICLE (LNP) PATENT PORTFOLIO AND A SUBSIDIARY OF ROIVANT SCIENCES LTD.

GENEVANT SCIENCES AND ARBUTUS BIOPHARMA ANNOUNCE $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA

MODERNA TO PAY GENEVANT AND ARBUTUS $950 MILLION UPFRONT AND AN ADDITIONAL $1.3 BILLION CONTINGENT UPON A FAVORABLE RESOLUTION OF MODERNA'S SECTION 1498 APPEAL IF THE $1.3 BILLION PAYMENT IS REALIZED, THIS SETTLEMENT WILL BE THE LARGEST DISCLOSED PATENT SETTLEMENT PAID IN THE PHARMACEUTICAL INDUSTRY AND THE SECOND LARGEST IN ANY INDUSTRY SETTLEMENT HOLDS MODERNA ACCOUNTABLE FOR INFRINGEMENT AND PROVIDES FOR THE COURT TO ENTER JUDGMENT OF NO INVALIDITY ON THE FOUR GENEVANT/ARBUTUS PATENTS ASSERTED IN THE CASE GENEVANT GRANTS MODERNA A GLOBAL NON-EXCLUSIVE LICENSE TO ITS LNP DELIVERY TECHNOLOGY FOR SM-102-CONTAINING MRNA VACCINES FOR INFECTIOUS DISEASE AND A COVENANT NOT TO SUE FOR CERTAIN GENEVANT/ARBUTUS PATENTS AND MODERNA PRODUCTS, ENDING ALL PATENT-INFRINGEMENT LITIGATION AGAINST MODERNA ARISING FROM ITS UNAUTHORIZED USE OF THE TECHNOLOGY IN ITS COVID-19 VACCINES PFIZER/BIONTECH LITIGATION IS ONGOING IN THE UNITED STATES FOLLOWING A FAVORABLE MARKMAN RULING ISSUED IN SEPTEMBER 2025; COMIRNATY SALES REPRESENT ~2/3 OF GLOBAL COVID-MRNA VACCINE SALES TO DATE ROIVANT'S BOARD OF DIRECTORS HAS APPROVED A $1 BILLION SHARE REPURCHASE PROGRAM, INCLUSIVE OF THE $500 MILLION AUTHORIZATION THAT WAS APPROVED IN JUNE 2025 ROIVANT WILL HOST AN INVESTOR CALL TO DISCUSS THESE UPDATES TODAY, MARCH 3, 2026, AT 4:45 P.M. ET BASEL, SWITZERLAND AND LONDON AND NEW YORK, MARCH 03, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY ANNOUNCED THAT GENEVANT SCIENCES, A LEADING NUCLEIC ACID DELIVERY COMPANY WITH WORLD-CLASS PLATFORMS AND A ROBUST LIPID NANOPARTICLE (LNP) PATENT PORTFOLIO AND A SUBSIDIARY OF ROIVANT, AND ARBUTUS BIOPHARMA CORPORATION (NASDAQ: ABUS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON INFECTIOUS DISEASE, HAVE ENTERED INTO A $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA, INC. TO RESOLVE ALL U.S. AND INTERNATIONAL ENFORCEMENT ACTIONS INVOLVING MODERNA'S UNAUTHORIZED USE OF GENEVANT'S AND ARBUTUS' LNP DELIVERY TECHNOLOGY IN ITS COVID-19 VACCINES, INCLUDING S

ROIVANT ANNOUNCES GENEVANT SCIENCES' AND ARBUTUS BIOPHARMA'S $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA

MCOMBRIAX IS THE WORLD'S FIRST FLU PLUS COVID COMBINATION VACCINE TO RECEIVE A POSITIVE CHMP OPINION RECOMMENDING MARKETING AUTHORIZATION AND REPRESENTS MODERNA'S FOURTH VACCINE TO RECEIVE A POSITIVE CHMP OPINION MCOMBRIAX WILL BE MADE AVAILABLE IN THE EUROPEAN UNION, SUBJECT TO FINAL EUROPEAN COMMISSION AUTHORIZATION AND NATIONAL REGULATORY AND ACCESS PROCEDURES CAMBRIDGE, MASSACHUSETTS / ACCESS NEWSWIRE / FEBRUARY 27, 2026 / MODERNA, INC. (NASDAQ:MRNA) TODAY ANNOUNCED THAT THE EUROPEAN MEDICINES AGENCY'S (EMA) COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ADOPTED A POSITIVE OPINION RECOMMENDING MARKETING AUTHORIZATION IN THE EUROPEAN UNION FOR MCOMBRIAX (MRNA-1083), MODERNA'S COMBINATION VACCINE INDICATED FOR ACTIVE IMMUNIZATION FOR THE PREVENTION OF INFLUENZA AND COVID-19 CAUSED BY SARS-COV-2 IN INDIVIDUALS 50 YEARS OF AGE AND OLDER. "THE CHMP'S POSITIVE OPINION REPRESENTS AN IMPORTANT MILESTONE FOR RESPIRATORY VIRUS VACCINATION AND FOR MODERNA, WITH THE INTRODUCTION OF THE WORLD'S FIRST FLU PLUS COVID COMBINATION VACCINE.

EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ADOPTS POSITIVE OPINION RECOMMENDING MARKETING AUTHORIZATION OF MCOMBRIAX, MODERNA'S MRNA COMBINATION VACCINE AGAINST INFLUENZA AND COVID-19

CAMBRIDGE, MASSACHUSETTS / ACCESS NEWSWIRE / FEBRUARY 19, 2026 / MODERNA, INC. (NASDAQ:MRNA), TODAY ANNOUNCED ITS PARTICIPATION IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: TD COWEN 46TH ANNUAL HEALTHCARE CONFERENCE, ON TUESDAY, MARCH 3RD AT 1:50PM ET BARCLAYS 28TH ANNUAL GLOBAL HEALTHCARE CONFERENCE, ON TUESDAY, MARCH 10TH AT 9:30AM ET A LIVE WEBCAST OF EACH OF THESE PRESENTATIONS WILL BE AVAILABLE UNDER "EVENTS AND PRESENTATIONS" IN THE INVESTORS SECTION OF THE MODERNA WEBSITE AT INVESTORS.MODERNATX.COM. A REPLAY OF EACH WEBCAST WILL BE ARCHIVED ON MODERNA'S WEBSITE FOR AT LEAST 30 DAYS FOLLOWING THE PRESENTATION.

MODERNA TO PRESENT AT UPCOMING CONFERENCES IN MARCH 2026

MNEXSPIKE IS THE THIRD MODERNA VACCINE AUTHORIZED IN THE EUROPEAN UNION, STRENGTHENING THE COMPANY'S RESPIRATORY VACCINE PORTFOLIO IN EUROPE CAMBRIDGE, MA / ACCESS NEWSWIRE / FEBRUARY 17, 2026 / MODERNA, INC. (NASDAQ:MRNA) TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) HAS GRANTED MARKETING AUTHORIZATION FOR MNEXSPIKE (MRNA-1283), A NEW COVID VACCINE, FOR ACTIVE IMMUNIZATION TO PREVENT COVID-19 CAUSED BY SARS-COV-2 IN INDIVIDUALS AGED 12 YEARS AND OLDER. THIS MARKETING AUTHORIZATION FOLLOWS THE POSITIVE OPINION ADOPTED BY THE EUROPEAN MEDICINES AGENCY'S (EMA) COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) AND MARKS MODERNA'S THIRD PRODUCT AUTHORIZED IN THE EUROPEAN UNION, ALONGSIDE SPIKEVAX AND MRESVIA, FURTHER STRENGTHENING THE COMPANY'S RESPIRATORY VACCINE PORTFOLIO IN EUROPE.

MODERNA RECEIVES EUROPEAN COMMISSION MARKETING AUTHORIZATION FOR COVID-19 VACCINE MNEXSPIKE

REPORTS FOURTH QUARTER REVENUE OF $0.7 BILLION, GAAP NET LOSS OF $(0.8) BILLION AND GAAP EPS OF $(2.11) REPORTS FULL-YEAR REVENUE OF $1.9 BILLION, GAAP NET LOSS OF $(2.8) BILLION AND GAAP DILUTED EPS OF $(7.26) REITERATES PLAN TO DELIVER UP TO 10% REVENUE GROWTH AND GAAP OPERATING EXPENSE REDUCTIONS IN 2026 ANNOUNCES INFLUENZA VACCINE FILING ACCEPTED FOR REGULATORY REVIEW IN THE EU, CANADA AND AUSTRALIA; COMPANY RECEIVED REFUSAL-TO-FILE LETTER FROM U.S. FDA AND HAS REQUESTED TYPE A MEETING TO UNDERSTAND PATH FORWARD ANNOUNCES NOROVIRUS PHASE 3 TRIAL FULLY ENROLLED WITH A DATA READOUT EXPECTED IN 2026 ANNOUNCES FULL ENROLLMENT OF PHASE 2 INTISMERAN AUTOGENE TRIAL IN MUSCLE INVASIVE BLADDER CANCER CAMBRIDGE, MA / ACCESS NEWSWIRE / FEBRUARY 13, 2026 / MODERNA, INC. (NASDAQ:MRNA) TODAY REPORTED FINANCIAL RESULTS AND PROVIDED BUSINESS UPDATES FOR THE FOURTH QUARTER OF 2025. "IN 2025, WE SHARPENED OUR COMMERCIAL EXECUTION, LAUNCHED OUR THIRD PRODUCT AND BROUGHT ONLINE THREE INTERNATIONAL MANUFACTURING SITES, WHILE ADVANCING OUR MRNA PIPELINE.

MODERNA REPORTS FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

SIGNED MEMORANDUM OF UNDERSTANDING SUPPORTS "PLAN MEXICO," MEXICO'S STRATEGIC INITIATIVE TO BUILD A LOCAL MRNA ECOSYSTEM AND STRENGTHEN HEALTH SECURITY STRATEGIC AGREEMENT WILL ENABLE ACCESS TO MODERNA'S RESPIRATORY VACCINE PORTFOLIO AS WELL AS A TECHNOLOGY TRANSFER TO LABORATORIOS LIOMONT FOR DOMESTIC MANUFACTURING OF MODERNA'S COVID-19 VACCINE CAMBRIDGE, MA / ACCESS NEWSWIRE / FEBRUARY 10, 2026 / MODERNA, INC. (NASDAQ:MRNA) TODAY ANNOUNCED IT HAS SIGNED A MEMORANDUM OF UNDERSTANDING (MOU) FOR A LONG-TERM STRATEGIC AGREEMENT WITH THE MEXICAN GOVERNMENT, LABORATORIOS DE BIOLGICOS Y REACTIVOS DE MEXICO (BIRMEX), AND LABORATORIOS LIOMONT (LIOMONT), TO ENHANCE MEXICO'S HEALTH SOVEREIGNTY AND MRNA MANUFACTURING RESILIENCE. THE FIVE-YEAR AGREEMENT WILL INCLUDE THE SUPPLY OF MODERNA'S RESPIRATORY VACCINE PORTFOLIO, AS WELL AS TECHNOLOGY TRANSFER TO LIOMONT, A MEXICAN PHARMACEUTICAL COMPANY WITH STATE-OF-THE-ART MANUFACTURING FACILITIES, TO PRODUCE MRNA-1273, MODERNA'S COVID-19 VACCINE, AND ESTABLISH A RELIABLE IN-COUNTRY SUPPLY OF RESPIRATORY VACCINES.

MODERNA TO ENTER INTO LONG-TERM STRATEGIC AGREEMENT WITH THE GOVERNMENT OF MEXICO

MIAMI, FEB. 04, 2026 (GLOBE NEWSWIRE) -- DEFIANCE ETFS TODAY ANNOUNCED THE LAUNCH OF THE DEFIANCE DAILY TARGET 2X LONG MRNA ETF (MRNX) , EXPANDING ITS LINEUP OF SINGLE-STOCK LEVERAGED ETFS DESIGNED FOR ACTIVE TRADERS SEEKING AMPLIFIED EXPOSURE TO INNOVATIVE COMPANIES AT THE FOREFRONT OF BIOTECHNOLOGY AND LIFE SCIENCES. MRNX IS DESIGNED FOR TRADERS SEEKING MAGNIFIED, SHORT-TERM BULLISH EXPOSURE TO MODERNA, INC. (NASDAQ: MRNA), A BIOTECHNOLOGY COMPANY KNOWN FOR ITS MESSENGER RNA (MRNA)BASED MEDICINES AND VACCINE DEVELOPMENT PLATFORM.

DEFIANCE LAUNCHES MRNX: THE FIRST DAILY 2X LONG ETF FOR MODERNA, INC.

CAMBRIDGE, MASSACHUSETTS / ACCESS NEWSWIRE / JANUARY 30, 2026 / MODERNA, INC. (NASDAQ:MRNA) TODAY ANNOUNCED THAT DAVID BERMAN, M.D., PH.D. HAS BEEN APPOINTED AS THE COMPANY'S CHIEF DEVELOPMENT OFFICER, BEGINNING MARCH 2, 2026.

DR. DAVID BERMAN TO JOIN MODERNA AS CHIEF DEVELOPMENT OFFICER

MRNA-3927 IS A STRONG STRATEGIC FIT WITH RECORDATI'S RARE METABOLIC PORTFOLIO COLLABORATION COMBINES MODERNA'S EXPERTISE IN MRNA TECHNOLOGY FOR RARE METABOLIC DISORDERS WITH RECORDATI'S ESTABLISHED GLOBAL RARE DISEASE COMMERCIAL INFRASTRUCTURE MODERNA WILL CONTINUE TO LEAD DEVELOPMENT FOR MRNA-3927, AND IF APPROVED, RECORDATI WILL LEAD GLOBAL COMMERCIALIZATION EFFORTS MILAN, 29 JANUARY 2026  RECORDATI TODAY ANNOUNCED THAT IT HAS ENTERED INTO A COLLABORATION AND LICENSE AGREEMENT WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE MRNA-3927, AN INVESTIGATIONAL PRODUCT FOR THE TREATMENT OF PROPIONIC ACIDEMIA (PA). UNDER THE TERMS OF THE AGREEMENT, MODERNA WILL CONTINUE TO LEAD THE DEVELOPMENT OF MRNA-3927, IN COLLABORATION WITH RECORDATI, AND IF APPROVED, RECORDATI WILL LEAD GLOBAL COMMERCIALIZATION.

RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE MRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA

CAMBRIDGE, MA / ACCESS NEWSWIRE / JANUARY 26, 2026 / MODERNA, INC. (NASDAQ:MRNA), TODAY ANNOUNCED THAT IT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 8:00 A.M. ET ON FRIDAY, FEBRUARY 13, 2026 TO REPORT ITS FOURTH QUARTER 2025 FINANCIAL RESULTS, AND PROVIDE A CORPORATE UPDATE.

MODERNA TO REPORT FOURTH QUARTER 2025 FINANCIAL RESULTS ON FRIDAY, FEBRUARY 13, 2026

AT A MEDIAN FIVE-YEAR PRE-PLANNED FOLLOW-UP OF THE PHASE 2B KEYNOTE-942/MRNA-4157-P201 STUDY, INTISMERAN AUTOGENE IN COMBINATION WITH KEYTRUDA REDUCED THE RISK OF RECURRENCE OR DEATH BY 49% (HR=0.510; [95% CI, 0.294-0.887]) COMPARED TO KEYTRUDA ALONE THE COMPANIES PLAN TO PRESENT FURTHER DATA FROM FOLLOW UP ANALYSES OF THE STUDY'S PRIMARY AND SECONDARY ENDPOINTS AT A FUTURE MEDICAL CONFERENCE EIGHT PHASE 2 AND PHASE 3 CLINICAL TRIALS UNDERWAY ACROSS MULTIPLE TUMOR TYPES INCLUDING MELANOMA, NON-SMALL CELL LUNG CANCER, BLADDER CANCER AND RENAL CELL CARCINOMA CAMBRIDGE, MA AND RAHWAY, NJ / ACCESS NEWSWIRE / JANUARY 20, 2026 / MODERNA, INC. (NASDAQ:MRNA) AND MERCK (NYSE:MRK), KNOWN AS MSD OUTSIDE OF THE UNITED STATES AND CANADA, TODAY ANNOUNCED MEDIAN FIVE-YEAR FOLLOW-UP DATA FROM THE PHASE 2B KEYNOTE-942/MRNA-4157-P201 STUDY, EVALUATING INTISMERAN AUTOGENE (MRNA-4157 OR V940), AN INVESTIGATIONAL MRNA-BASED INDIVIDUALIZED NEOANTIGEN THERAPY (INT), IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB), MERCK'S ANTI-PD-1 THERAPY, IN PATIENTS WITH HIGH-RISK MELANOMA (STAGE III/IV) FOLLOWING COMPLETE RESECTION. IN THIS PRE-PLANNED ANALYSIS, ADJUVANT TREATMENT WITH INTISMERAN AUTOGENE IN COMBINATION WITH KEYTRUDA CONTINUED TO DEMONSTRATE SUSTAINED AND CLINICALLY MEANINGFUL IMPROVEMENT IN THE STUDY'S PRIMARY ENDPOINT, RECURRENCE-FREE SURVIVAL (RFS), REDUCING THE RISK OF RECURRENCE OR DEATH BY 49% (HR=0.510; [95% CI, 0.294-0.887]; ONE-SIDED NOMINAL P=0.0075) COMPARED TO KEYTRUDA ALONE.

MODERNA & MERCK ANNOUNCE 5-YEAR DATA FOR INTISMERAN AUTOGENE IN COMBINATION WITH KEYTRUDA(R) (PEMBROLIZUMAB) DEMONSTRATED SUSTAINED IMPROVEMENT IN THE PRIMARY ENDPOINT OF RECURRENCE-FREE SURVIVAL IN PATIENTS WITH HIGH-RISK STAGE III/IV MELANOMA FOLLOWING COMPLETE RESECTION

Moderna, Inc.

MRNA

Price

Financial Reports

No items found.

Press Releases

Moderna, Inc.

MRNA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

MRNA